Showing 601-610 of 10105 results for "".
Therapies in Practice: Barrier Repair as an Element of Psoriasis Management
https://practicaldermatology.com/topics/practice-management/therapies-in-practice-barrier-repair-as-an-element-of-psoriasis-management/21977/Data suggest psoriasis involves barrier damage; topical barrier repair may support clearance.An Update on Hair Transplantation
https://practicaldermatology.com/topics/general-topics/an-update-on-hair-transplantation/22021/For the dermatologists interested in expanding the service menu or offering the best advice to patients, here's an update on the latest advancements in hair transplantation.Part 3, 1726 nm lasers: How to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is to be patient
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24341/Chapter 3 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is toDWTV Extra: Image-Guided SRT Consensus
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-image-guided-srt-consensus/35744/Jacob Scott, MD, chairman of the Dermatology Association of Radiation Therapy (DART), discusses an expert panel's recommendations on the role of image-guided superficial radiation therapy in the treatment of non melanoma skin cancer, which were published in an article titled "The Role of Image-GuidePart 4, 1726 nm lasers: Handling referred patients who are already on different treatment regimens
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24342/Chapter 4 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about handling referred patients who are already on different treatment regimens.Treating Psoriasis with FDA-Approved Medications in 2020
https://practicaldermatology.com/topics/psoriasis/treating-psoriasis-with-fda-approved-medications-in-2020/23212/A reference for all of the FDA-approved medications separated into topical treatments and systemic treatments.The State of Private Equity in 2024: Impact on the Practice of Dermatology
https://practicaldermatology.com/columns/practice-management/state-private-equity-2024-impact-practice-dermatology/27173/Physician Growth Partners recently published a white paper, “State of Dermatology Private Equity,” that evaluated market trends, strategies, and more. Practical Dermatology® spoke exclusively with CEO Michael Kroin about how the evolution of private equity is impacting the everyday practitioner andCalling Out Hesitation on Systemics
https://practicaldermatology.com/programs/practical-dermatology/calling-out-hesitation-on-systemics/35703/The latest news and updates, plus Jason E. Hawkes, MD, MS, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss why dermatologists should not be reluctant to prescribe systemic therapies, and Linda F. Stein Gold, MD, discusses the importance of an ever-expanding aStudy Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.The Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succe